Research
Hormonal
GLP-1 receptor agonists (GLP-1RAs) have adverse events associated with their increased use.
Practitioners should be aware of the potential adverse events when prescribing GLP-1RAs.
StrongSupportsmedium confidence
Adverse events associated with GLP-1RAs have become evident with their increased use.
Why this rating
The claim is based on a comprehensive review of literature.
Source
Impact of GLP-1 receptor agonists on gastrointestinal function and symptoms
Rosita Frazier et al. · Expert Review of Gastroenterology & Hepatology · 2025
DOI 10.1080/17474124.2025.2579117
reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →